Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet.
暂无分享,去创建一个
P. Little | Suowen Xu | Peiqing Liu | Yi Cai | Xiaoqian Wu | Xiaoyan Shen | Heqing Huang | Y. Huang | K. Le | Futian Tang | Tianyun Lan | Hua Wang
[1] Peiqing Liu,et al. Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression. , 2011, European journal of pharmacology.
[2] Y. Huang,et al. Evaluation of foam cell formation in cultured macrophages: an improved method with Oil Red O staining and DiI-oxLDL uptake , 2010, Cytotechnology.
[3] Jun-Rong Du,et al. Tanshinone IIA inhibits smooth muscle proliferation and intimal hyperplasia in the rat carotid balloon-injured model through inhibition of MAPK signaling pathway. , 2010, Journal of ethnopharmacology.
[4] R. Virmani,et al. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[5] Suowen Xu,et al. Development of an optimized protocol for primary culture of smooth muscle cells from rat thoracic aortas , 2009, Cytotechnology.
[6] E. Zhou,et al. Tanshinone II(A) elicited vasodilation in rat coronary arteriole: roles of nitric oxide and potassium channels. , 2009, European journal of pharmacology.
[7] F. Howe,et al. Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms , 2009, Circulation.
[8] De-Pei Liu,et al. Human Paraoxonase Gene Cluster Transgenic Overexpression Represses Atherogenesis and Promotes Atherosclerotic Plaque Stability in ApoE-Null Mice , 2009, Circulation research.
[9] Yan Zhu,et al. The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS , 2009, The Journal of Steroid Biochemistry and Molecular Biology.
[10] Soo-Ho Choi,et al. Macrophages Generate Reactive Oxygen Species in Response to Minimally Oxidized Low-Density Lipoprotein: Toll-Like Receptor 4– and Spleen Tyrosine Kinase–Dependent Activation of NADPH Oxidase 2 , 2009, Circulation research.
[11] N. Webb. Getting to the core of atherosclerosis , 2008, Nature Medicine.
[12] Young-Chae Chang,et al. Tanshinone IIA from Salvia miltiorrhiza BUNGE inhibits human aortic smooth muscle cell migration and MMP‐9 activity through AKT signaling pathway , 2008, Journal of cellular biochemistry.
[13] T. Hibi,et al. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. , 2008, Pharmacology & therapeutics.
[14] Hui Zhang,et al. Tanshinone IIA downregulates the CD40 expression and decreases MMP-2 activity on atherosclerosis induced by high fatty diet in rabbit. , 2008, Journal of ethnopharmacology.
[15] P. Komesaroff,et al. A Preparation of Herbal Medicine Salvia miltiorrhiza Reduces Expression of Intercellular Adhesion Molecule-1 and Development of Atherosclerosis in Apolipoprotein E-Deficient Mice , 2008, Journal of cardiovascular pharmacology.
[16] Hui Zhang,et al. Tanshinone IIA inhibits atherosclerotic plaque formation by down-regulating MMP-2 and MMP-9 expression in rabbits fed a high-fat diet. , 2007, Life sciences.
[17] R. Parker,et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 , 2007, Nature.
[18] Ping Wang,et al. Tanshinone II A attenuates atherosclerotic calcification in rat model by inhibition of oxidative stress. , 2007, Vascular pharmacology.
[19] Hong-Sheng Zhang,et al. Nrf2 is involved in the effect of tanshinone IIA on intracellular redox status in human aortic smooth muscle cells. , 2007, Biochemical pharmacology.
[20] Horng-mo Lee,et al. Tanshinone IIA from Salvia miltiorrhiza induces heme oxygenase-1 expression and inhibits lipopolysaccharide-induced nitric oxide expression in RAW 264.7 cells. , 2007, Mitochondrion.
[21] Weirong Wang,et al. Protective effect of tanshinone IIA on human umbilical vein endothelial cell injured by hydrogen peroxide and its mechanism. , 2006, Journal of ethnopharmacology.
[22] S. Jang,et al. Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. , 2006, European journal of pharmacology.
[23] T. Cheng. Danshen: a popular chinese cardiac herbal drug. , 2006, Journal of the American College of Cardiology.
[24] Hong Wang,et al. Tanshinone: an inhibitor of proliferation of vascular smooth muscle cells. , 2005, Journal of ethnopharmacology.
[25] Z. Qian,et al. Tanshinone inhibits intimal hyperplasia in the ligated carotid artery in mice. , 2005, Journal of ethnopharmacology.
[26] G. Angelini,et al. Plaque Rupture After Short Periods of Fat Feeding in the Apolipoprotein E–Knockout Mouse: Model Characterization and Effects of Pravastatin Treatment , 2005, Circulation.
[27] J. Keaney,et al. Role of oxidative modifications in atherosclerosis. , 2004, Physiological reviews.
[28] R. Park,et al. Tanshinone IIA from Salvia miltiorrhiza Inhibits Inducible Nitric Oxide Synthase Expression and Production of TNF-α, IL-1β and IL-6 in Activated RAW 264.7 Cells , 2003 .
[29] P. Libby. Inflammation in atherosclerosis , 2002, Nature.
[30] C. Kataoka,et al. New Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Atherosclerosis in Apolipoprotein E-Knockout Mice , 2001, Circulation.
[31] X. Niu,et al. Tanshinone II-A inhibits low density lipoprotein oxidation in vitro , 2000, Free radical research.
[32] R. Ross,et al. Atherosclerosis is an Inflammatory Disease , 1998 .
[33] Daniel Steinberg,et al. Low Density Lipoprotein Oxidation and Its Pathobiological Significance* , 1997, The Journal of Biological Chemistry.
[34] N. Maeda,et al. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.
[35] E. Rubin,et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.
[36] R. Williams,et al. Quantitative assessment of atherosclerotic lesions in mice. , 1987, Atherosclerosis.
[37] Ming-Wei Wang,et al. The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism. , 2009, Endocrinology.
[38] R. Ross,et al. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.